Trial updates on injectable oncolytic immunotherapy for metastatic melanoma

  • April 17, 2014

NEW YORK — Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, highlights the contrasting results from the two completed phase 3 trials involving velimogene aliplasmid and talimogene laherparepvec.

Andtbacka reviewed data demonstrating that velimogene aliplasmid (Allovectin, Vical) failed to exhibit a statistically significant improvement vs. first-line chemotherapy for either the primary endpoint of objective response rate at 24 weeks or more after randomization or the secondary endpoint of overall survival.

More »

Additional headlines from HemOnc Today Melanoma and Cutaneous Malignancies meeting

See All »